Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Notes Payables (2019 - 2025)

Bioadaptives' Notes Payables history spans 7 years, with the latest figure at $32096.0 for Q4 2025.

  • Quarterly results put Notes Payables at $32096.0 for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $32096.0 (changed 0.0% YoY), and the annual figure for FY2025 was $32096.0, changed 0.0%.
  • Notes Payables for Q4 2025 was $32096.0 at Bioadaptives, down from $359300.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $423888.0 in Q3 2022 to a low of $10246.0 in Q2 2022.
  • The 5-year median for Notes Payables is $177357.5 (2021), against an average of $186765.2.
  • The sharpest move saw Notes Payables plummeted 95.01% in 2022, then surged 2981.57% in 2023.
  • Year by year, Notes Payables stood at $33715.0 in 2021, then skyrocketed by 1032.41% to $381793.0 in 2022, then dropped by 15.75% to $321658.0 in 2023, then tumbled by 90.02% to $32096.0 in 2024, then changed by 0.0% to $32096.0 in 2025.
  • According to Business Quant data, Notes Payables over the past three periods came in at $32096.0, $359300.0, and $311000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.